NCT03672331: MyPeBS

My Personalized Breast Screening

Active, enrolled NA Last updated 18 September 2025

What this trial tests

NA trial testing Mammogram in Breast Screening in 53,142 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

18 July 2019

Primary endpoint
31 August 2027

31 December 2027

Quick facts

Lead sponsor	UNICANCER
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	53,142
Start date	18 July 2019
Primary completion	31 August 2027
Estimated completion	31 December 2027
Sites	6 locations across France, Italy, Belgium, United Kingdom, Israel, Spain

Drugs / interventions tested

• Mammogram
• Ultrasound
• MRI — full drug profile →
• Tomosynthesis

Conditions studied

• Breast Screening — all drugs for Breast Screening →

Sponsor

UNICANCER — full company profile →

Who can join

Adults 40 to 70, female only, with Breast Screening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

MyPeBS is an international randomized, open-label, multicentric, study assessing the effectiveness of a risk-based breast cancer screening strategy (using clinical risk scores and polymorphisms) compared to standard screening (according to the current national guidelines in each participating country) in detecting stage 2 or higher breast cancers.

Women will be differentially screened for 4 years and then, after an end-of-study mammogram, they will return to the routine screening practice. The main study endpoint will be measured at the end of the four years of intervention.

Furthermore, follow up data will be collected for 15 years from study entry for evaluation of long-term cumulative breast cancer incidence and breast cancer-specific survival

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. The current status of risk-stratified breast screening.
   Clift AK, Dodwell D, Lord S, Petrou S, et al · · 2022 · cited 85× · PMID 34703006 · DOI 10.1038/s41416-021-01550-3
2. Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial.
   Roux A, Cholerton R, Sicsic J, Moumjid N, et al · · 2022 · cited 72× · PMID 35524202 · DOI 10.1186/s12885-022-09484-6
3. Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment.
   Zeinomar N, Chung WK. · · 2021 · cited 19× · PMID 33253037 · DOI 10.7326/m20-5874
4. Feasibility of personalized screening and prevention recommendations in the general population through breast cancer risk assessment: results from a dedicated risk clinic.
   Saghatchian M, Abehsera M, Yamgnane A, Geyl C, et al · · 2022 · cited 13× · PMID 34994879 · DOI 10.1007/s10549-021-06445-8
5. Acceptability of risk-based breast cancer screening among professionals and healthcare providers from 6 countries contributing to the MyPeBS study.
   Roux A, Hervouet L, Stefano FD, French DP, et al · · 2025 · cited 5× · PMID 40089664 · DOI 10.1186/s12885-025-13848-z
6. Toward Application of Polygenic Risk Scores to Both Enhance and Deintensify Breast Cancer Screening.
   Maxwell KN, Domchek SM. · · 2024 · cited 4× · PMID 38422469 · DOI 10.1200/jco.24.00029
7. Evaluating the prognostic performance of a polygenic risk score for breast cancer risk stratification.
   Olsen M, Fischer K, Bossuyt PM, Goetghebeur E. · · 2021 · cited 4× · PMID 34930164 · DOI 10.1186/s12885-021-08937-8
8. Insights into genetic modifiers of breast cancer risk in carriers of BRCA1 and BRCA2 pathogenic variants.
   Dwornik R, Białkowska K. · · 2025 · cited 1× · PMID 40296163 · DOI 10.1186/s13053-025-00313-y